New radiation combo aims to boost immunotherapy in advanced lung cancer
NCT ID NCT05615142
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding low-dose radiation and targeted radiation (SBRT) to an immunotherapy drug (PD-1 inhibitor) is safe for people with stage IV non-small cell lung cancer who have not responded to standard treatments. About 9 participants will receive the combination therapy to check for side effects and see if it helps control the cancer. The goal is to find a tolerable way to potentially improve treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW-DOSE RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?